Protagonist Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 27, 2024

PTGX$136.26+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)


· · Year Ended December 31,
· 2023 · 2022 · 2021
Cash Flows from Operating Activities · · · ·
Net loss	$(78,955)	$(127,393)	$(125,551)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	29,293	24,202	16,395
Operating lease right-of-use asset amortization	2,335	2,335	1,962
(Accretion) amortization of discount/premium on marketable securities	(4,569)	(549)	1,830
Depreciation	977	1,034	813
Other	194	—	—
Changes in operating assets and liabilities:
Research and development tax incentive receivable	—	2,686	(1,775)
Receivable from collaboration partner	(9,990)	1,556	860
Prepaid expenses and other assets	1,753	3,754	(3,227)
Accounts payable	(2,868)	2,045	(1,390)
Payable to collaboration partner	(66)	(830)	(1,833)
Accrued expenses and other payables	(5,597)	(12,715)	19,097
Deferred revenue	—	(1,601)	(12,876)
Operating lease liability	(2,743)	(2,661)	(2,049)
Other liabilities	—	—	(121)
Net cash used in operating activities	(70,236)	(108,137)	(107,865)
Cash Flows from Investing Activities
Purchase of marketable securities	(191,045)	(214,874)	(286,589)
Proceeds from maturities of marketable securities	152,396	307,137	271,830
Purchases of property and equipment	(609)	(795)	(1,101)
Net cash (used in) provided by investing activities	(39,258)	91,468	(15,860)
Cash Flows from Financing Activities
Proceeds from public offering of common stock, net of issuance costs	107,798	—	123,829
Proceeds from at-the-market offering, net of issuance costs	24,302	14,553	—
Proceeds from exercise of Warrants in exchange for issuance of Pre-Funded Warrants	33,813	—	—
Proceeds from issuance of common stock upon exercise of Warrants	559	—	—
Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan	4,774	4,448	6,283
Tax withholding payments related to net settlement of restricted stock units	(769)	(188)	(189)
Issuance costs related to prior period common stock offering	—	25	—
Net cash provided by financing activities	170,477	18,838	129,923
Effect of exchange rate changes on cash, cash equivalents and restricted cash	—	(90)	(126)
Net increase in cash, cash equivalents and restricted cash	60,983	2,079	6,072
Cash, cash equivalents and restricted cash, beginning of period	125,969	123,890	117,818
Cash, cash equivalents and restricted cash, end of period	$186,952	$125,969	$123,890
Supplemental Disclosure of Non-Cash Financing and Investing Information:
Purchases of property and equipment in accounts payable and accrued liabilities	$61	$19	$143
Issuance costs related to common stock offering included in accrued liabilities and other payables	$—	$—	$25

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.